While both Sasaki et al. [31] and Tanabe et al. [36] investigated CCR5 inhibition in colitis-associated CRC models, their studies emphasize distinct cellular mechanisms—immune modulation versus stromal remodeling—underscoring the multifaceted role of the CCL3/CCR5 axis in tumor development. This evidence concerns the gene CCL3 and colitis.